Pefloxacin is a quinolone antibiotic used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.
Clinical data | |
---|---|
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 100% |
Protein binding | 20–30% |
Metabolism | Hepatic |
Elimination half-life | 8.6 hours |
Excretion | Mostly renal, also biliary |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.067.807 |
Chemical and physical data | |
Formula | C17H20FN3O3 |
Molar mass | 333.363 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
Pefloxacin was developed in 1979 and approved in France for human use in 1985.[1]
Pefloxacin has been increasingly used as a veterinary medicine to treat microbial infections.[4]
Pefloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV,[5] which is an enzyme necessary to separate, replicated DNA, thereby inhibiting cell division.
Tendinitis and rupture, usually of the Achilles tendon, are class-effects of the fluoroquinolones, most frequently reported with pefloxacin.[6] The estimated risk of tendon damage during pefloxacin therapy has been estimated by the French authorities in 2000 to be 1 case per 23,130 treatment days as compared to ciprofloxacin where it has been estimated to be 1 case per 779,600.[7]